Hematologic neoplasms: Dendritic cells vaccines in motion

Research output: Contribution to journalReview articlepeer-review


Dendritic cells (DCs) are bone-marrow-derived immune cells accounted for a key role in cancer vaccination as potent antigen-presenting cells within the immune system. Cancer microenvironment can modulate DCs maturation resulting in their accumulation into functional states associated with a reduced antitumor immune response. In this regard, a successful cancer vaccine needs to mount a potent antitumor immune response able to overcome the immunosuppressive tumor milieu. As a consequence, DCs-based approaches are a safe and promising strategy for improving the therapeutic efficacy in hematological malignancies, particularly in combinations with additional treatments. This review summarizes the most significant evidence about the immunotherapeutic strategies performed to target hematologic neoplasms including the tumoral associated antigens (TAA) pulsed on DCs, whole tumor cell vaccines or leukemia-derived DCs.

Original languageEnglish
Pages (from-to)181-190
Number of pages10
JournalClinical Immunology
Publication statusPublished - Oct 1 2017


  • Cancer vaccination
  • DC vaccine
  • Dendritic cells
  • Hematologic neoplasms
  • Hematological malignancies
  • Immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Hematologic neoplasms: Dendritic cells vaccines in motion'. Together they form a unique fingerprint.

Cite this